BrainZell returns from US investment summit
The company mapped 9 US locations and initiated collaboration with Mayo Clinic Research for CNS drug discovery.
See the latest news and media coverage for BrainZell. We track all announcements, press releases, and industry mentions in real time, all in one place.
High-throughput drug discovery using brain organoids
brainzell.comLast updated
In short: BrainZell advanced its AI-native brain organoid platform for CNS drug discovery and initiated a collaboration with the Mayo Clinic Research.
The company mapped 9 US locations and initiated collaboration with Mayo Clinic Research for CNS drug discovery.
CEO Petra Szeszula joins a Swedish delegation to Washington D.C. for meetings with government, investors, and partners, then continues to Boston.
Selected by Hello Tomorrow from 4,800 applications for human brain organoids replacing animal testing. CEO pitches at Amsterdam Summit in June 2026.
They screen drug candidates on patient-derived organoids, including rare diseases, using data from failed trials for better models.
Track BrainZell and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.